Testing SFL-0821 for people with FSHD
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study is testing a new medicine, SFL-0821, to see if it is safe and useful for people with FSHD. It may help if it works, but it is still experimental.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed FSHD type 1 or 2 by genetic testing
- Disease severity within a specific range (Clinical Severity Score 1.5 to 4)
- Can walk 10 meters in 5 to 14 seconds, using at most a cane or ankle brace
- Willing to have a muscle biopsy before and after the study drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called SAT-3247 to see if it can safely improve muscle strength in people with facioscapulohumeral muscular dystrophy (FSHD), a condition that causes muscle weakness, especially in the face, shoulders, and legs. Participating may help you and future patients by finding a treatment that could slow or reduce muscle loss.
This study creates a patient-driven health and research platform for people with FSHD. It aims to collect information to better understand the condition and improve future research and care.
This study tests a new medicine called SRP-1001 to see if it can help people with a type of muscular dystrophy called FSHD1. It aims to slow down muscle weakness and improve quality of life.
This trial tests a new stem cell treatment (ULSC) for people with FSHD, a type of muscular dystrophy. It aims to see if the treatment is safe and if it can help improve arm strength and daily movement.
This trial studies how well certain physical/movement tests work in people with facioscapulohumeral muscular dystrophy (FSHD). It may help clinicians measure changes more accurately and tailor care over time.
This study tests whether a drug called apitegromab can help improve muscle function in people with facioscapulohumeral muscular dystrophy (FSHD). It is for adults aged 18-60 who have mild to moderate symptoms and can walk or run 10 meters in 5 seconds or less.
Hear when a new Facioscapulohumeral Muscular Dystrophy (FSHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.